Lumida
/CHRS
⌘K
Coherus Oncology Inc

Coherus Oncology Inc

CHRS
$1.33USD-0.75%-0.01 today

MARKET CAP

205.5M

P/E (TTM)

0.8x

FWD P/E

DAY RANGE

$1 – $1

52W RANGE

$1
$3

AI Summary

Stalk
TrimMedium

CHRS remains in a Stage 4 decline with a confirmed LH/LL regime and price below downward-sloping EMAs, supporting a medium-term bearish bias. The recent bounce into the 9/21EMA zone lacks follow-through, making immediate selling unfavorable. We defer execution, trimming into rallies at EMAs and prior resistance areas rather than chasing current extension.

  • Q2 2026 revenue $13.6M (+37% YoY; +15% QoQ) driven by Lactorsi.
  • Cash $105.3M after cutting R&D to $21.4M and SG&A to $21M.
  • Net loss narrowed to $33.3M (-$0.22/share) remains significant.
Full analysis →
Insider Trades18 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jan 20, 2026SellCHRSBryan J McmichaelChief Financial Officer1,715$1.55$205.5M-49.16%+22.02%$2.7K-7.47%Trim
Jan 20, 2026SellCHRSDennis M LanfearPresident & CEO11,839$1.55$205.5M-49.16%+22.02%$18.4K-1.73%Trim
Jan 20, 2025SellCHRSBryan J McmichaelChief Financial Officer1,711$1.39$205.5M-49.16%+22.02%$2.4K-6.94%Trim
Jan 20, 2025SellCHRSPaul ReiderChief Commercial Officer4,858$1.39$205.5M-49.16%+22.02%$6.8K-5.59%Trim
Jan 20, 2025SellCHRSDennis M LanfearPresident & CEO11,810$1.39$205.5M-49.16%+22.02%$16.4K-1.69%Trim
Jan 7, 2025SellCHRSBryan J McmichaelChief Financial Officer1,711$1.57$205.5M-49.16%+22.02%$2.7K-6.49%Trim
Jan 4, 2025SellCHRSPaul ReiderChief Commercial Officer2,277$1.66$205.5M-49.16%+22.02%$3.8K-0.91%Trim
Jan 4, 2025SellCHRSDennis M LanfearPresident & CEO11,810$1.66$205.5M-49.16%+22.02%$19.6K-1.67%Trim
Dec 13, 2024SellCHRSPaul ReiderChief Commercial Officer2,073$1.61$205.5M-49.16%+22.02%$3.3K-2.27%Trim
Jan 20, 2024SellCHRSBryan J Mcmichael1,707$2.44$205.5M-49.16%+22.02%$4.2K-6.92%Trim
Jan 20, 2024SellCHRSPaul ReiderChief Commercial Officer4,854$2.44$205.5M-49.16%+22.02%$11.8K-5.64%Trim
Jan 20, 2024SellCHRSDennis M LanfearPresident & CEO11,218$2.44$205.5M-49.16%+22.02%$27.4K-1.56%Trim
Jan 7, 2024SellCHRSBryan J Mcmichael1,707$2.87$205.5M-49.16%+22.02%$4.9K-6.47%Trim
Jan 4, 2024SellCHRSPaul ReiderChief Commercial Officer2,275$2.92$205.5M-49.16%+22.02%$6.6K-2.57%Trim
Jan 4, 2024SellCHRSDennis M LanfearPresident & CEO11,781$2.92$205.5M-49.16%+22.02%$34.4K-0.90%Trim
Dec 31, 2023SellCHRSMcdavid StilwellChief Financial Officer18,440$3.33$205.5M-49.16%+22.02%$61.4K-19.67%Trim
Dec 13, 2023SellCHRSPaul ReiderChief Commercial Officer2,049$2.37$205.5M-49.16%+22.02%$4.9K-2.27%Trim
Nov 22, 2023BuyCHRSDennis M LanfearPresident & CEO523,040$1.67$205.5M-49.16%+22.02%$874.8K+3.33%Trim